Eisai Co., Ltd. (FRA:EII)

Germany flag Germany · Delayed Price · Currency is EUR
25.59
-0.41 (-1.58%)
Last updated: Dec 5, 2025, 8:18 AM CET
-15.54%
Market Cap 7.28B
Revenue (ttm) 4.63B
Net Income (ttm) 284.33M
Shares Out n/a
EPS (ttm) 1.01
PE Ratio 25.60
Forward PE n/a
Dividend 0.95 (3.69%)
Ex-Dividend Date Sep 29, 2025
Volume n/a
Average Volume 25
Open 25.59
Previous Close 26.00
Day's Range 25.59 - 25.59
52-Week Range 21.45 - 31.41
Beta n/a
RSI 51.46
Earnings Date Feb 9, 2026

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer’s disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for prim... [Read more]

Industry Pharmaceutical Preparations
Founded 1941
Employees 10,917
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol EII
Full Company Profile

Financial Performance

In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.